This article needs attention from an expert in Viruses.(March 2015)
PVS-RIPO consists of a genetically modified nonpathogenic version of the oral poliovirus Sabin type 1. The internal ribosome entry site (IRES) on the poliovirus was replaced with the IRES from human rhinovirus type 2 (HRV2), to avoid neurovirulence. Once administered, the virus enters and begins replicating within cells that express CD155/Necl5, which is an onco-fetal cell adhesion molecule that is common across solid tumors.
The FDA approved clinical trials with PVS-RIPO in brain tumor patients recently. Since May 2012, five brain tumor patients have been treated. Remarkably, there have been no toxic side effects with PVS-RIPO whatsoever, even at the highest possible dose (10 billion infectious virus particles).
- Brown, Michael C.; Dobrikova, Elena Y.; Dobrikov, Mikhail I.; Walton, Ross W.; Gemberling, Sarah L.; Nair, Smita K.; ...; Gromeier, Matthias (1 November 2014). "Oncolytic polio virotherapy of cancer". Cancer. 120 (21): 3277–3286. doi:10.1002/cncr.28862. PMC 4205207. PMID 24939611.
- Oncolytic Poliovirus Receives Breakthrough Designation for Glioblastoma. May 2016
- "Targeting Cancer with Genetically Engineered Poliovirus (PVS-RIPO)". The Preston Robert Tisch Brain Tumor Center.
- Tate, Nick (30 March 2015). "Can the Polio Virus Cure Cancer?". Newsmax. Retrieved 31 March 2015.
- "Using polio to kill cancer: A producers' notebook". 60 Minutes Overtime. CBS News. 29 March 2015. Retrieved 31 March 2015.